Reviewing Puma Biotechnology (NASDAQ:PBYI) & Its Rivals

Puma Biotechnology (NASDAQ: PBYI) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Puma Biotechnology to similar businesses based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, earnings, risk and valuation.

Volatility and Risk

Puma Biotechnology has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Puma Biotechnology’s competitors have a beta of 1.48, indicating that their average stock price is 48% more volatile than the S&P 500.


This table compares Puma Biotechnology and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Puma Biotechnology N/A -208.58% -145.91%
Puma Biotechnology Competitors -4,594.03% -35.12% -43.24%

Earnings & Valuation

This table compares Puma Biotechnology and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Puma Biotechnology N/A -$276.01 million -11.68
Puma Biotechnology Competitors $217.40 million -$39.40 million -63.10

Puma Biotechnology’s competitors have higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

96.0% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 21.1% of Puma Biotechnology shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Puma Biotechnology and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology 0 1 8 0 2.89
Puma Biotechnology Competitors 572 2506 6735 133 2.65

Puma Biotechnology currently has a consensus price target of $130.67, indicating a potential upside of 36.54%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.75%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Puma Biotechnology is more favorable than its competitors.


Puma Biotechnology beats its competitors on 7 of the 13 factors compared.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with's FREE daily email newsletter.

Leave a Reply